Engineering biomimetic tissue barrier models on chips: From design and fabrication to applications in disease modeling and drug screening
- PMID: 41072391
- PMCID: PMC12646612
- DOI: 10.1016/j.biomaterials.2025.123739
Engineering biomimetic tissue barrier models on chips: From design and fabrication to applications in disease modeling and drug screening
Abstract
Replicating the in vitro properties of tissue barriers-such as the blood-brain barrier, gut, skin, lung, kidney, retina, nasal epithelium, and placenta-is crucial for many applications, including drug screening, studying molecular transport, drug delivery, and disease modeling in preclinical studies. Organ-on-a-chip (OoC) platforms are advanced three-dimensional (3D) in vitro models that aim to replicate various aspects of organ functionality within microfluidic systems by providing microenvironments akin to native tissue. When used to model the interface between two different tissue compartments, OoC technology offers a promising platform for more accurately replicating the physiology and pathophysiology of various tissue barriers in the body. This review focuses on the state-of-the-art biomimetic tissue barrier models, ranging from two-channel tissue barrier-on-a-chip systems with a thin porous membrane to hydrogel-based membrane models. Specifically, it explores the engineering of tissue barrier-on-a-chip platforms, highlighting various fabrication techniques for microfluidic chips and membranes, as well as methods for functional characterization of the engineered tissue barriers. Additionally, we discuss the development of organ-specific barrier models and multi-organ-on-a-chip systems for studying inter-organ communication. Finally, we highlight the current challenges in the field and future directions in advancing tissue barrier modeling using OoC technology.
Keywords: Disease modeling; Drug screening; Drug transport; Membrane; Microfabrication; Microfluidics; Organ-on-a-chip; Tissue-tissue interface.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest VML is co-founder, CEO and shareholder of HepaPredict AB, as well as co-founders and shareholders of Shanghai Hepo Biotechnology Ltd.
Figures
References
-
- Kimlin L, Kassis J, Virador V. 3D in vitro tissue models and their potential for drug screening. Expert Opin Drug Discov. 2013. Dec 1;8(12):1455–66. - PubMed
-
- Kavand H, Nasiri R, Herland A. Advanced Materials and Sensors for Microphysiological Systems: Focus on Electronic and Electro-optical Interfaces. Adv Mater. 2021. Dec 16;n/a(n/a):2107876. - PubMed
-
- Youhanna S, Kemas AM, Preiss L, Zhou Y, Shen JX, Cakal SD, et al. Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives. Pharmacol Rev. 2022. Jan 1;74(1):141–206. - PubMed
-
- McGonigle P, Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem Pharmacol. 2014;87(1):162–71. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
